Is Schering's cost squeeze boosting productivity?

Halfway through Schering-Plough's "productivity program"--a.k.a. its $1.5 billion cost-cutting plans--the company's numbers show productivity plateauing, rather than getting better. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.